Evolving Treatment Strategies in the Management of Metastatic Melanoma: Optimizing Immunotherapy Approaches for Improved Outcomes

Evolving Treatment Strategies in the Management of Metastatic Melanoma: Optimizing Immunotherapy Approaches for Improved Outcomes is organized by National Association of Managed Care Physicians (NAMCP).,This activity is valid from August 1, 2022, to August 1, 2023,Description:,Melanoma is the most serious type of skin cancer. It occurs in skin cells called melanocytes, and while it is predominantly found in the skin, it can occur in any area of the body that contains melanocytes. Melanoma will be found in approximately 106,110 people in the United States in 2021 according to the National Cancer Institute. While it is the least common among skin cancers, it is by far the deadliest, with 7,180 people expected to die in 2021. Both of those numbers have been rising in recent years. In the early stages of melanoma, the prognosis is usually good for patients, but when the melanoma becomes metastatic and spreads to other areas of the body, the prognosis is especially poor. Fortunately for patients with metastatic melanoma, and the physicians that treat them, significant progress has been made in the treatment of this deadly disease over the past 10 years, especially in the area of immunotherapies. With several new therapy options and indications recently approved for patients, including as an adjuvant treatment in melanoma, it is critical to educate medical directors, practicing physicians, nurses, and other healthcare professionals on the recent updates in treatment options and guideline recommendations.,Upon completion of this activity, participants will be able to:,• Examine the clinical and economic burden of metastatic melanoma, including factors that contribute to poor prognosis and increased costs,• Differentiate current and emerging treatments for patients with metastatic melanoma,• Assess recent and emerging clinical data on the safety and efficacy of novel immunotherapeutic approaches for treating patients with melanoma,• Explore strategies to properly identify patients for neoadjuvant and adjuvant systemic therapies in resectable melanoma,• Identify immune-related adverse events and appropriate management strategies associated with immunotherapy treatment of melanoma,• Apply current evidence to individualize clinically and managed care decision-making for patients with metastatic melanoma,Additional details will be posted as soon as information is available.